Trial Profile
Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Blinatumomab With or Without Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Filgrastim; Folinic acid; Mercaptopurine; Mesna; Methotrexate; Ofatumumab; Pegfilgrastim; Prednisone; Rituximab; Vincristine
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 21 Sep 2023 Planned End Date changed from 1 Nov 2023 to 1 Nov 2026.
- 21 Sep 2023 Planned primary completion date changed from 1 Nov 2023 to 1 Nov 2026.
- 15 Jun 2023 Results assessing efficacy and safety of hyper-CVAD with sequential blinatumomab, with or without INO, in ptswith newly diagnosed Ph-negative B-cell ALL presented at the 28th Congress of the European Haematology Association